Masako Nakamura serves as the President and Chief Operating Officer at Chrysalis Genetics since September 2024. Prior experience includes roles as Head and General Manager of International Markets at Amylyx Pharmaceuticals and Senior Vice President, Head of Asia at Alnylam Pharmaceuticals. Masako Nakamura has held various leadership positions at Aegerion Pharmaceuticals and the Genzyme organization, including Vice President roles in multiple disciplines such as Global Marketing and Commercial Strategy. In earlier career stages, Masako Nakamura worked at Genetics Institute as Director of Hematology Products and initiated tenure at Genzyme as Product Manager for Lysosomal Storage Disorders. Educational credentials include a BA in English, History, and Asian Studies from Connecticut College, complemented by executive education in Accounting and Finance, Business Management, Leadership, and Value Creation from HBS and Wharton.